Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 34

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
267) 
    $(9,761,349) 
    $(7,821,944)

    Net loss available to common stockholders per share of common stock, basic and diluted* 
    $(9.09) 
    $(13.16) 
    $(18.09) 
    $(25.79)

    Weighted average number of shares used in calculating net loss per share, basic and diluted* 
     574,923  
     305,140  
     539,538  
     303,336 

*Retroactively restated
for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-2

INDAPTUS
THERAPEUTICS, INC.

Unaudited
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

    Shares*  
    Amount*  
    Capital  
    deficit  
    Total 

    Common stock  
    Additional  paid in  
    Accumulated  

    Shares*  
    Amount*  
    Capital*  
    deficit  
    Total 

    Balance, January 1, 2024 
     300,037  
    $3,000  
    $57,490,654  
    $(45,417,156) 
    $12,076,498 
  
    Stock-based compensation 
     -  
     -  
     774,691  
     -  
     774,691 
  
    Issuance of shares of common stock, net of issuance costs 
     4,920  
     49  
     315,998  
     -  
     316,047 
  
    Net loss 
     -  
     -  
     -  
     (3,806,677) 
     (3,806,677)

    Balance, March 31, 2024 
     304,957  
    $3,049  
    $58,581,343  
    $(49,223,833) 
    $9,360,559 

    Stock-based compensation 
     -  
     -  
     782,852  
     -  
     782,852 
  
    Issuance of shares of